Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC-COMET: Neoadjuvant chemoradiotherapy plus metformin in locally advanced rectal cancer
jRCTs011200001Phase 2Completed
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metformin in rectal cancer. Primary endpoints: Dose-limiting toxicity (DLT) and Pathological complete response rate (central pathological diagnosis). Started Aug 2020; status: completed.
02
Drugs
metformin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on jRCTs011200001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011200001.